Company profile
Vaccine Antigen Design | DIOSynVax | Cambridge
DIOSynVax: Achieving dramatic improvements to how we protect humanity against deadly pathogens. Discover advanced solutions to vaccine antigen design.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
RP01SH01 | Transaction MzUxMDU1NjcxOWFkaXF6a2N4
Published 04 Apr 2026 11:07
SH01 | Transaction MzUwMjQ4ODMzOGFkaXF6a2N4 | Paper/PDF filed
Published 04 Apr 2026 11:07
Last confirmation statement made up date
Last accounts made up date
AP01 | Transaction MzQ0MzA3NDAwM2FkaXF6a2N4
Published 13 Nov 2024 02:49
AA | Transaction MzQzNzM5MjQ4MmFkaXF6a2N4
Published 26 Sep 2024 02:22
CS01 | Transaction MzQzMTk2NzE2M2FkaXF6a2N4
Published 13 Aug 2024 10:39
Company registered at Companies House
1 Apr 2025 to 31 Mar 2027
The global spread of H5Nx influenza, with nearly 900 reported human cases and a fatality rate exceeding 50% in major strains, underscores the urgent need for innovative vaccine solutions. The diversity of H5Nx clades causing outbreaks reveals our inability to predict which strain from which clade might become pandemic. This situation exposes the limitatio...
1 Oct 2023 to 30 Jun 2025
DIOSynVax, a clinical-stage biotechnology company based in Cambridge, UK, is working on a groundbreaking project to develop a novel vaccine against four diseases which cause outbreaks of high consequence to human health including Ebola, Lassa, Marburg and mpox . The primary goal of our project is to protect populations in low and middle-income countries (...
1 Apr 2022 to 31 Mar 2023
We have developed a pre-clinical trivalent Haemorrhagic Fever Vaccine (HFV) candidate able to combat three important African haemorrhagic fever viruses: Lassa Fever virus (LASV), Ebola (EBOV) and Marburg (MARV) viruses. Separately, a fourth vaccine monovalent candidate against Crimean-Congo Haemorrhagic Fever (CCHF) has been developed by our collaborator ...
1 Dec 2021 to 31 Jan 2022
Vaccines that protect against multiple related viruses have been developed using DIOSynVax technology. This broadly protective approach is needed for the Coronaviruses such as SARS-COV-2 and SARS-COV, two of numerous related viruses that have the potential to cause future outbreaks from zoonotic reservoirs. We have designed antigens to induce an immune re...
1 Sep 2020 to 31 Dec 2022
Safe and highly effective vaccines are the most promising medical interventions for the prevention of infectious diseases. At the time of writing, there have been over 5 million cases and 330,000 deaths reported to the WHO. The coronavirus, referred to as SARS-CoV-2, causes a respiratory disease termed COVID-19\. Current experimental Spike-based coronavir...
1 Jun 2020 to 31 Mar 2021
no public description
1 Apr 2019 to 31 Dec 2022
"There has never been a greater need for better influenza (Flu) vaccines to replace traditionally produced seasonal Flu vaccines that generate variable levels of protection. Seasonal Flu vaccines are imperfect and fail from time to time resulting in huge economic costs to the NHS and other national health services in this country and globally, when they f...
